ASX Filings

Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective

April 21, 2016

Change of Director's Interest Notice - MS

April 7, 2016

Change of Director's Interest Notice - MB

April 7, 2016

Change of Director's Interest Notice - GK

April 7, 2016

Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial

March 30, 2016

Chairman's Address to the EGM

March 7, 2016

Results of the Extraordinary General Meeting

March 7, 2016

CEO's Presentation to the EGM

March 7, 2016

Half Year Report and Accounts

February 26, 2016

Notice of Extraordinary General Meeting/Proxy Form

February 5, 2016